Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - February 2014


Advances and Progress in Drug Design

17 Feb 2014 - 18 Feb 2014 - London, UK



Bookmark and Share


SPONSORED BY CHEMICAL COMPUTING GROUP

SMi are proud to present the 13th annual Advances and Progress in Drug Design conference, convening in Central London on Monday 17 and Tuesday 18 February 2014. This exciting event will focus on new approaches and will offer attendees the chance to hear from leading industry experts on lead optimisation strategies, SBDD and FBDD. 

Past events have received positive feedback from the industry including ‘Well selected talks, stimulating atmosphere’ – Sanofi, ‘Very good interactive meeting, overall excellent’ – Pfizer and ‘a very good meeting – right number of people’ - AstraZeneca

Advances and Progress in Drug Design Conference will build on the success of our previous events and bring together a unique mix of senior executives from all over industry and academia and will be an unrivalled forum for problem-solving discussion and debate. 

Benefits of Attending:

Understand pharma's current and future drug design strategies and highlight the challenges the industry is currently facing

Explore the latest approaches in structure-based drug design

Evaluate lead optimisation strategies

Consider the latest in fragment based drug discovery as the future of drug design

Linking HTS and FBDD - examining alternative approaches in drug discovery

Participate in two post conference interactive workshops hosted by Vernalis on New Approaches in ‘Structure Based Design’, and the 2nd hosted by The Research Network on ‘Chemically Modified Biologicals’

Ample opportunity for peer to peer networking with two morning coffee breaks, two networking lunches, two afternoon tea sessions and a networking drinks reception hosted by Chemical Computing Group on end of day one.

Key Speakers for 2014

John Mathias, Head of Medicinal Chemistry - Inflammation & Remodelling, Pfizer

Sudharsan Sridharan, Scientist, MedImmune

Tom Heightman, Senior Director, Astex Pharmaceuticals

Amaury Ernesto Fernandez-Montalvan, Lab Head, High Throughput Screening, Bayer HealthCare Pharmaceuticals

Karl-Heinz Baringhaus, Head of R&D, Sanofi-Aventis

Andreas Kuglstatter, Head of Protein Crystallography, Roche Chemische Unternehmungen AG

Dr Neil Press, Director, Novartis

Paul Labute, CEO, Chemical Computing Group

Andrea Bortolato, Senior Computational Chemistry, Heptares Therapeutics

Paul Brennan, Group Head/PI, Nuffield Department of Medicine

For further information visit us online at www.drug-design.co.uk

Alternatively, contact John Collins on +44 (0)20 7827 6734 or email jcollins@smi-online.co.uk




Further information
Scientific News
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
Safer, Cheaper, Greener and More Efficient System for Organic Synthesis
The new medium not only supports organic synthesis it also produces considerably higher yields of product than pure organic solvents.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Collaboration to Develop Cancer Therapeutics
Major license agreement with Merck, enabled by Blavatnik Biomedical Accelerator, aims to develop therapy for most common form of acute leukemia.
Faster UVA Molecular Analysis Technology
There are people in the world – chemical engineers, astronomers, national defense scientists investigating an explosion – who need to know just what something is made of, down to the molecular level.
Scientists Synthesize Anti-Cancer Agent
A team led by Rice University synthetic organic chemist K.C. Nicolaou has developed a new process for the synthesis of a series of potent anti-cancer agents originally found in bacteria.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!